The aim of this study is to evaluate the effectiveness Dydrogesterone in PPOS protocols for IVF/ICSI cycles or Oocyte cryopreservation both blocking LH surge as well number metaphase II oocytes. 550 plus 186 oocyte from January 2018 December 2020, no age restriction. All patients were given Follitropin delta (Rekovelle®, Ferring Pharmaceuticals) Menotropin (Menopur®, a fixed daily SC dose. Clin...

Abstract Background Central precocious puberty (CPP) results from early reactivation of the hypothalamic-pituitary-gonadal (HPG) axis. Four monogenic causes CPP have been described (KISS, KISS1R MKRN3 and DLK1). Rare loss-of-function mutations DLK1, a maternally imprinted gene located on chromosome 14q32.2, were identified in families with CPP. Both inherited or de novo DLK1 these affected fami...

background: the purpose of present study was to evaluate the role of pre-ovulatory gnrh agonist therapy on ivf outcomes in gnrh antagonist cycles. methods: in this prospective study we recruited 100 infertile women undergoing ivf cycles with gnrh antagonists. the patients were assigned to two groups: group a (the study group, n=42) were assigned for receiving hcg+triptorelin for the final oocyt...

This systematic review aims to assess the efficacy of aromatase inhibitors (AIs) in treating pain symptoms caused by endometriosis. A comprehensive literature search was conducted to identify all the published studies evaluating the efficacy of type II nonsteroidal aromatase inhibitors (anastrozole and letrozole) in treating endometriosis-related pain symptoms. The MEDLINE, EMBASE, PubMed, and ...

BACKGROUND Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer. METHODS In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppressio...